




Schizofrenia, consumo di sostanze ed esordio precoce


SERGIO DE FILIPPIS

Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort



Cannabis– esordio sintomatologico

Sesso	N°	Età primo ricovero	Età ricovero	Inizio cannabis	Età Esordio	ΔT cannabis-esordio	N° ricoveri precedenti	N° ricoveri successivi
M	145	20,60 ± 4,491	24,59 ± 4,595	16,31 ± 2,53	19,11 ± 3,196	2,78 ± 2,628	2,99 ± 2,419	1,50 ± 2,595
F	75	20,18 ± 4,982	23,64 ± 5,753	15,18 ± 2,260	17,55 ± 2,721	2,36 ± 1,891	2,73 ± 2,051	1,41 ± 2,051
Tot	210	20,51 ± 4,547	24,40 ± 4,835	16,08 ± 2,513	18,80 ± 3,159	2,70 ± 2,496	2,94 ± 2,343	1,48 ± 2,399



Probability of Transition to Psychosis in Individuals at Clinical High Risk An Updated Meta-analysis 2021

Figure 2. Meta-analytic Cumulative Risk of Transition to Psychosis in Individuals at Clinical High Risk for Psychosis






Figure 3. Meta-analytical Kaplan-Meier Failure Function (1 - Survival) and Hazard Rate of Transition to Psychosis in Individuals at Clinical High Risk for Psychosis



Rischio di transizione in psicosi per soggetti CHR:
25% dopo tre anni
35% dopo 10 anni

The neurobiology of drug addiction: cross-species insights into the dysfunction and recovery of the prefrontal cortex




Differenze di genere

- **Differenze nell'utilizzo:**


1. Gli uomini hanno una spiccata tendenza al poliutilizzo
2. Le donne sono solitamente monoutilizzatrici

- **Differenze nell'esordio psicopatologico:**


1. Gli uomini hanno un esordio caratterizzato da sintomi positivi
2. Le donne hanno un esordio caratterizzato da disturbi del comportamento



Cannabis and synaptic reprogramming of the developing brain



Mappe di differenze nei valori di FA: TRS vs controlli sani



$p < 0.05$ corretto per
multiple comparazioni

RADIAZIONE TALAMICA
ANTERIORE

FASCICOLO LONGITUDINALE
SUPERIORE

FASCICOLO LONGITUDINALE
INFERIORE


FASCICOLO FRONTO-
OCCIPITALE INFERIORE

FASCICOLO UNCINATO

FORCEPS MINOR

TRATTO CORTICO-SPINALE


Mappe di differenze nei valori di FA: TRS vs controlli sani



Correlazione tra i livelli di glutammato totale (glutammato più glutammina) e le prestazioni sulla memoria verbale del BACS.

Più alti sono i livelli, peggiori sono le prestazioni.

TARGET FARMACOLOGICI INNOVATIVI



First-episode schizophrenia

Either:

Agree on the choice of antipsychotic medication
with patient¹ and/or carer

Or, if not possible:

Start **second-generation** antipsychotic medication^{2,3}

Titrate, as necessary, to minimum effective dose
(see section on 'minimum effective dose'—this chapter)

Adjust dosage regimen according to therapeutic
response and tolerability/safety

Assess over 2–3 weeks*

Effective

Continue at dose
established as effective
Consider switching to
depot/long-acting injection
before discharge**

No effect

Change drug and
follow above process


Not effective

Clozapine***

Not tolerated or poor medication
adherence


If poor adherence related to poor
tolerability, discuss with patient and
change to drug with more
favourable side-effect profile
If poor adherence related to other
factors, consider early use of
depot/long-acting injection**

Understanding and Predicting Variability in Response to Treatment in Psychotic Disorders: *In Vivo* Findings




- La resistenza al trattamento è osservata in circa il 15-20% degli esordi schizofrenici aumentando nel tempo di un ulteriore 15%
- Un esame del sistema presinaptico nella psicosi resistente al trattamento ha evidenziato una minore capacità di sintesi della dopamina striatale
- Volume ventricolare aumentato e alterazioni della sostanza grigia e bianca sono associati a scarsa risposta clinica
- La Causa può essere un uso eccessivo di cannabis o antipsicotici?
- Supersensitività recettoriale dopaminergica?

Drug Reward And Addiction In Pentients with Early-Episode Schizophrenia




- Il 35% del campione totale NON ha una ricaduta e **assume Agonisti Parziali**
- Solo il 6% del campione totale che **assume Agonisti Parziali** ha una ricaduta

- Il 8.75% del campione totale NON ha una ricaduta e **assume FGA**
- Il 15.4% del campione totale ha una ricaduta e **assume FGA**




Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia




70.396 pazienti; età media 42 anni, periodo osservazione dal 2004 al 2019



Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia



Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia




Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders




BIS = Birchwood Insight Scale

The course and concomitants of depression in first-episode schizophrenia spectrum disorders: A 24-month longitudinal study



Prevention and Treatment of Opioid Misuse and Addiction: A Review



Two-injection start: an alternative start regimen with aripiprazole once-monthly

